Global Regime of Pharmaceutical Governance
These are all complex problems which have many different causes but it is not inappropriate to package them all as part of a global regime of pharmaceuticals development and delivery
In some degree this regime operates differently in different countries and is open to national determination but increasingly determined globally; with pressures from WTO, bilateral FTAs, US bullying etc.
The transnational pharmaceutical industries constitute a major set of players in shaping global environment with strong support through business world generally (WEF) and the OECD countries (especially those with big home based TNCs).
Complex issues and wide range of complex packages of solutions have been brought forward.
Reform of this regime to maximise the health gain from modern pharmaceuticals calls for a global mobilisation of civil society and national governments and international organisations to reform the global governance arrangements which shape this regime
Calls for civil society in all countries to take responsibility for these issues; to examine the role of their own countries, the position of their own governments, including Australia
We also need to consider arguments for reform of patent laws and contemporary policies and practices in relation to the use of patent laws (eg non-exclusive use patents, prizes instead of patents, advance purchase commitments).
Strategies of change
PHN international network working on shared issues with a focus on the barriers to health development of people in low and middle income countries and marginalised people everywhere
PHM Oz has among its strategic objectives:
- focusing on the barriers to health development in Australia and focusing on the international dynamics; the shared international experience
- building solidarity and support in High Income Countries like Australia for the struggle for health in Low and Middle Income Countries